← 홈

ADC

167개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 167개
ADCBiologicstaleGenentech, Inc.Phase 2

Taselisib (Taselisib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 50%임상시험 10상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 1.4%임상시험 10상태 DISCONTINUED
ADCBiologicstaleThe Thai Lymphoma Study GroupPhase 2

B-MAD chemotherapy (B-MAD chemotherapy)

Extranodal NK/T-cell Lymphoma · Extranodal NK/T-cell Lymphoma

#ExtranodalNKT-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 33.3%임상시험 9상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 2

CHEP (CHEP)

Lymphoma; Adult T-Cell Leukemia/Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 2%임상시험 9상태 RECRUITING
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab Vedotin, Rituximab (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleRochePhase 2

Zanubrutinib, Polatuzumab vedotin and Rituximab (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 9상태 ACTIVE
ADCBiologicstaleMedImmune LLCPhase 1

BL22 immunotoxin (BL22 immunotoxin)

Leukemia; Lymphoma · Leukemia

#Leukemia#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 0%임상시험 8상태 ACTIVE
ADCBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (MB-CART2019.1)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 8상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 2

PI3K-beta Inhibitor GSK2636771 (PI3K-beta Inhibitor GSK2636771)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 9%임상시험 8상태 RECRUITING
ADCBiologicstaleRochePhase 2

Pola-R- GemOx (Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin, Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx))

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 69.7%임상시험 6상태 RECRUITING
ADCBiologicstalePfizerPhase 2

BrECADD (BrECADD)

Hodgkin Lymphoma (Category) · Hodgkin Lymphoma (Category)

#HodgkinLymphomaCategory#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 5상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Larotrectinib Sulfate (Larotrectinib Sulfate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 60%임상시험 5상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

SAR3419 (SAR3419)

Diffuse Large B-cell Lymphoma · Acute Lymphocytic Leukaemia

#AcuteLymphocyticLeukaemia#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 5상태 ACTIVE
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD19A (SGN-CD19A)

Burkitt Lymphoma; Precursor B-cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 DISCONTINUED
ADCBiologicstaleRochePhase 3

polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
임상시험 4상태 RECRUITING
ADCBiologicstaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin, anti-PD-1 antibody.)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Bv-AVD-R (Bv-AVD-R)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING
ADCBiologicstaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING

5 / 9 페이지

← 이전다음 →